Clinical Trial Detail

NCT ID NCT00923130
Title Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

renal cell carcinoma

kidney cancer

Therapies

Bevacizumab + Ixabepilone

Age Groups: adult

No variant requirements are available.